@FiercePharma: ICYMI yesterday: Merck's Frazier joins top-paid pharma CEOs with a $25M package. Article | Follow @FiercePharma
@EricPFierce: Sounds like Walgreens would like to buy into another drug distributor like AmerisourceBergen. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: The coming generics threat to Pfizer's Viagra brand just got scarier. FiercePharmaMarketing report | Follow @CarlyHFierce
> The parents of a Vermont woman who died last year have sued Botox-maker Allergan ($AGN)--now part of Actavis ($ACT)--saying treatment of her cerebral palsy with the drug helped lead to her death and that the company didn't properly warn of risks. More
> Ireland's pharmaceutical industry has been boosted by a stream of significant new investments in recent years, according to a new report. More
> The FDA has approved a label update for Johnson & Johnson's ($JNJ) Zytiga that includes overall survival results in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Release
> FDA reviewers have recommended that the agency approve The Medicines Company's ($MDCO) once-rejected blood clot preventer. Report
> Santhera Pharmaceuticals may market a degenerative muscular disease drug on its own in the U.S. to secure a bigger share of revenue and longer patent protection. Report
Medical Device News
@FierceMedDev: EarlySense nabs Mitsui as Japan partner, investor and ups financing to $25M. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Medtronic joins St. Jude in leadless pacemaker market thanks to CE mark. Report | Follow @VarunSaxena2
@EmilyWFierce: Visual app acts as a "cheat sheet" for docs looking for a quick diagnosis. Wired story | Follow @EmilyWFierce
> Startup raises $4M for sterilization with vaporized hydrogen peroxide. More
> Baxter expanding its manufacturing plant in Arkansas amid preparations to spin off pharma biz. Story
Biotech News
@FierceBiotech: Galapagos' closely-watched rheumatoid arthritis drug filgotinib scores in PhIIb. Report | Follow @FierceBiotech
@JohnCFierce: Meanwhile, back in biotech boomland, Aduro prices at $17 a share. Over the range
$ADRO. Reuters story | Follow @JohnCFierce
> Bayer pours $100M into Bay Area R&D with eyes on hemophilia. Report
> Aduro pulls off a $119M IPO to fund its immuno-oncology pipeline. Story
> Dominant VC NEA gathers $3B, preps for another wave of biotech rounds. Article
Pharma Marketing News
> Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq. More
> Tech it out: Pfizer, AARP and UnitedHealthcare push innovation. Report
> J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1. More
> DTC ad viewers really do ask their doctors about new meds, survey finds. Story
> The coming generics threat to Pfizer's Viagra brand just got scarier. Article
Biotech Research News
> Focused on cell signaling, CHOP team preps for human mitochondrial drug study. Report
> UCLA team packs large cargo into cells. Item
> Scripps Parkinson's study points to a key enzyme as a potential drug target. More
> MIT team works on amping up a new approach to cancer immunotherapies. Story
> Chicago project highlights effects of an ancient Chinese cardio remedy. Article
Diagnostics News
> GE and Veracyte team up for disease diagnostic research collaboration. Item
> NIH awards $11M to develop tests for drug-resistant bacteria. Story
> FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. More
> Roche grabs CAPP Medical to gain ground in cancer Dx. News
> Biocartis joins forces with Microbiome for quick sepsis test. Article
And Finally... Australia is cutting off government welfare for anti-vaxxers. More